GSK plc (GSK)
| Market Cap | 97.84B |
| Revenue (ttm) | 43.24B |
| Net Income (ttm) | 7.39B |
| Shares Out | 4.03B |
| EPS (ttm) | 1.79 |
| PE Ratio | 27.33 |
| Forward PE | 10.85 |
| Dividend | $1.66 (3.40%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | 2,969,235 |
| Open | 48.90 |
| Previous Close | 48.88 |
| Day's Range | 48.56 - 48.99 |
| 52-Week Range | 31.72 - 49.31 |
| Beta | 0.23 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Oct 29, 2025 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsNews
GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)
GSK has been impressing me with strong revenue and EPS numbers for the eighth quarter in a row. Also, on December 12, depemokimab, GSK's anti-IL-5 antibody with 6-month dosing, received a positive EMA...
GSK gets EU regulator backing for expanded use of RSV vaccine
GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader ...
European health regulator recommends approval for GSK's twice yearly asthma drug
The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday.
US FDA approves GSK's oral treatment for gonorrhea
The U.S. Food and Drug Administration on Thursday approved GSK's oral treatment for gonorrhea, a sexually transmitted infection.
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
Oxford, UK and San Jose, California , 10th December 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-bas...
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
Vaccine makers expressed concern on Friday's decision by a U.S. advisory panel to scrap its long-standing recommendation that all infants receive a hepatitis B vaccine at birth, a shift that public he...
BREAKING: Trump strikes major deal with UK on drug pricing
FOX Business White House correspondent Edward Lawrence reports the details of President Donald Trump's pharmaceutical deal with the U.K. on 'Varney & Co.'
AnaptysBio shares tumble after legal fight with GSK over cancer drug license
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a par...
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties
GSK plc (NYSE: GSK) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. (NASDAQ: ANAB) in the Delaware Chancery Court.
GSK, AnaptysBio Sue Each Other Over Cancer Drug License
The companies accuse one another of breaching a licensing agreement for Jemperli, a drug used to treat some forms of endometrial cancer.
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a ...
GSK plc (GSK) Presents at Jefferies London Healthcare Conference 2025 Transcript
GSK plc ( GSK) Jefferies London Healthcare Conference 2025 November 19, 2025 4:30 AM EST Company Participants Tony Wood - Chief Scientific Officer and Head of R&D Conference Call Participants Michael...
The Best Healthcare Stock to Hold in Uncertain Times
GlaxoSmithKline is now known simply as GSK. GSK stock trades for 13 times earnings and barely 11 times free cash flow.
GlaxoSmithKline India reports higher second-quarter profit on specialty medicine growth
India's GlaxoSmithKline Pharmaceuticals reported slightly higher second-quarter profit on Thursday, led by steady demand for its specialty medicine portfolio.
3 Dividend Stocks for November 2025
This month's trio includes two ADRs.
GSK plc (GSK) Q3 2025 Earnings Call Transcript
GSK plc ( GSK) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Emma Walmsley - CEO & Director Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO of ViiV Healthcare...
GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026
British pharmaceutical giant GSK Plc (NYSE:GSK) on Wednesday reported upbeat third-quarter results and upgraded its full-year 2025 guidance.
GSK Raises Guidance After Sales, Earnings Growth
The drugmaker now expects 2025 sales growth between 6% to 7% when excluding currency movements, up from a 3% to 5% range.
GSK raises 2025 sales forecast after strong growth in specialty medicines
GSK raised its 2025 sales expectations on Wednesday after third-quarter results beat expectations, driven by double-digit growth in its specialty medicines, including HIV and oncology.
GSK shares fall as narrow approval of blood cancer drug limits US relaunch
GSK's London-listed shares fell nearly 2% on Friday after the U.S. Food and Drug Administration approved only one of two treatment combinations with the British firm's blood cancer drug, limiting the ...
FTSE 100 Index shares to watch: HSBC, Standard Chartered, Haleon, GSK
The FTSE 100 Index rose for four consecutive days and reached its all-time high of £9,578 as traders reacted to key earnings and macro data. It has jumped by over 27% from its lowest level this year.
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
PHILADELPHIA--(BUSINESS WIRE)-- #BelantamabMafodotin--Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma.
US FDA approve GSK's blood cancer treatment
The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in combination with other treatments, the company said on Thursday, paving the way for a relaunch...
UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug
The UK's drugs cost-effectiveness watchdog has given a positive recommendation for ViiV Healthcare's HIV drug, enabling access to the preventive medicine via the state health system in England and Wal...